BPI-16350

BPI-16350
Clinical data
Other names	BPI16350
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-8-yl)pyrimidin-2-amine;
PubChem CID	135181567;
Chemical and physical data
Formula	C28H32F2N8
Molar mass	518.617 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C6N5C(CCC6)C)F;
	InChI InChI=1S/C28H32F2N8/c1-3-36-9-11-37(12-10-36)17-19-7-8-24(31-15-19)33-28-32-16-22(30)26(35-28)20-13-21(29)27-23(14-20)38-18(2)5-4-6-25(38)34-27/h7-8,13-16,18H,3-6,9-12,17H2,1-2H3,(H,31,32,33,35); Key:XOJPAVACYRFOBK-UHFFFAOYSA-N;

BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer.^[1]^[2] It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research.^[3]

References

^ Gao, Shuiping; Liu, Ru-Jiao; Chen, Yang; Wang, Yi-qian; Chen, Hong; Zhang, Hui-juan; Ma, Tian-yi; Wang, Jia-bing; Hu, Xi-Chun; Zhang, Jian (28 March 2022). "A novel potent CDK4/6 inhibitor BPI-16350 in preclinical cancer models". doi:10.21203/rs.3.rs-1333630/v1. {{cite journal}}: Cite journal requires |journal= (help)
^ Ray-Coquard, Isabelle; Monk, Bradley J.; Lorusso, Domenica; Mahdi, Haider; Upadhyay, Vivek; Graul, Regina; Husain, Amreen; Mirza, Mansoor Raza; Slomovitz, Brian (31 October 2023). "The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma". International Journal of Gynecologic Cancer. 33 (12): 1943–1949. doi:10.1136/ijgc-2023-004739. ISSN 1048-891X. PMC 10804003. PMID 37907262. S2CID 264844023.
^ Zhang, Jian; Liu, Rujiao; Gao, Shuiping; Chen, Wenyan; Han, Xinghua; Ma, Yanjie; Ding, Lieming; Wang, Jiabing; Lan, Hong; Hu, Xichun (1 June 2023). "BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study". Journal of Clinical Oncology. 41 (16_suppl): e13051. doi:10.1200/JCO.2023.41.16_suppl.e13051. S2CID 259083530.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Gao, Shuiping; Liu, Ru-Jiao; Chen, Yang; Wang, Yi-qian; Chen, Hong; Zhang, Hui-juan; Ma, Tian-yi; Wang, Jia-bing; Hu, Xi-Chun; Zhang, Jian (28 March 2022). "A novel potent CDK4/6 inhibitor BPI-16350 in preclinical cancer models". doi:10.21203/rs.3.rs-1333630/v1. {{cite journal}}: Cite journal requires |journal= (help)

[2] Ray-Coquard, Isabelle; Monk, Bradley J.; Lorusso, Domenica; Mahdi, Haider; Upadhyay, Vivek; Graul, Regina; Husain, Amreen; Mirza, Mansoor Raza; Slomovitz, Brian (31 October 2023). "The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma". International Journal of Gynecologic Cancer. 33 (12): 1943–1949. doi:10.1136/ijgc-2023-004739. ISSN 1048-891X. PMC 10804003. PMID 37907262. S2CID 264844023.

[3] Zhang, Jian; Liu, Rujiao; Gao, Shuiping; Chen, Wenyan; Han, Xinghua; Ma, Yanjie; Ding, Lieming; Wang, Jiabing; Lan, Hong; Hu, Xichun (1 June 2023). "BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study". Journal of Clinical Oncology. 41 (16_suppl): e13051. doi:10.1200/JCO.2023.41.16_suppl.e13051. S2CID 259083530.

[1]

[2]

[3]